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Abstract  
Introduction: Celecoxib is a weakly acidic drug and has low aqueous solubility (3–
7 μg/ml). Low solubility of drugs in water results in poor bioavailability because the 
solubility of a drug is an important factor in determining its absorption rate. 
According to the Noyes–Whitney equation, the saturation solubility and dissolution 
rate of poorly water soluble drugs can be enhanced by reducing the particle size, 
which increases the total surface area. Nanocrystals possess outstanding features 
enabling to overcome the solubility problems of poorly soluble drugs. The objective 
of this study was to investigate the dissolution behavior improving effects of 
differently sized nanocrystals of a poorly soluble model drug, Celecoxib. 
Methods and Results: Nanocrystals were prepared by antisolvent precipitation 
followed by high pressure homogenization (HPH) technique in the presence of 
varying percentage of SLS as a stabilizer (0.2 or 0.4%) and rate of homogenization 
(26500 or 12500 rpm). The obtained nanoparticles were analyzed in terms of particle 
size distribution, polydispersity index, saturation solubility, thermal behavior (DSC) 
and dissolution behavior. The particle size of nanosuspensions was between 140 and 
532 nm with poly dispersibility index less than 0.5. That minimum of particle size 
relate to formulation which contained 0.4% stabilizer with rate of 26500 rpm. This 
formulation also revealed the highest saturation solubility (18.1 µg/ml) and 
dissolution efficiency compared to pure Celecoxib. The DSC results indicated the 
absence of any interactions between drug and stabilizer. These studies showed a 
decrease in crystalinity of Celecoxib.  
Conclusions: All microcrystals significantly (P<0.05) increased Celecoxib aqueous 
solubility and dissolution rate compared to plain drug. This result seemed to be due 
the significant particle size reduction and decreased drug crystallinity. Significant 
influence of increasing in rate of homogenizer on size reduction was observed.  As 
well as, high stabilizer concentration and rate of homogenizer had Significant 
influence on saturated solubility of Celecoxib compared to pure drug (P<0.05). DSC 
study showed that there is no change in the crystal structure of Celecoxib during the 
process and showed that nanocrystals exhibited decreased crystallinity.               
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